Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The VEGF family in cancer and antibody-based strategies for their inhibition.

Sullivan LA, Brekken RA.

MAbs. 2010 Mar-Apr;2(2):165-75. Review.

2.

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.

PMID:
18221053
3.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
4.

VEGF inhibitors in cancer therapy.

Cardones AR, Banez LL.

Curr Pharm Des. 2006;12(3):387-94. Review.

PMID:
16454752
5.

Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.

Homsi J, Daud AI.

Cancer Control. 2007 Jul;14(3):285-94. Review.

7.

Angiogenesis inhibitors in the treatment of lung cancer.

Sun S, Schiller JH.

Crit Rev Oncol Hematol. 2007 May;62(2):93-104. Epub 2007 Feb 15. Review.

PMID:
17306557
8.

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Langer CJ, Natale RB.

Semin Oncol. 2005 Dec;32(6 Suppl 10):S23-9. Review.

PMID:
16459176
9.

Vascular endothelial growth factor and bevacitumab in breast cancer.

Bando H.

Breast Cancer. 2007;14(2):163-73. Review.

10.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
11.

Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T.

Curr Med Chem. 2011;18(21):3136-55. Review.

PMID:
21671856
12.
13.
14.
15.

Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.

Ellis LM, Rosen L, Gordon MS.

Clin Adv Hematol Oncol. 2006 Jan;4(1):suppl 1-10; quz 11-2.

PMID:
16562372
16.

Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.

Zhang C, Tan C, Ding H, Xin T, Jiang Y.

Curr Pharm Des. 2012;18(20):2921-35. Review.

PMID:
22571661
17.

VEGF as a therapeutic target in cancer.

Ferrara N.

Oncology. 2005;69 Suppl 3:11-6. Epub 2005 Nov 21. Review.

PMID:
16301831
18.

[The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].

Grépin R, Pagès G.

J Soc Biol. 2009;203(2):181-92. doi: 10.1051/jbio/2009022. Epub 2009 Jun 16. Review. French.

PMID:
19527632
19.

Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.

Tandle A, Libutti SK.

Clin Adv Hematol Oncol. 2003 Jan;1(1):41-8. Review.

PMID:
16227959
20.

Vascular endothelial growth factor receptors: expression and function in solid tumors.

Wey JS, Stoeltzing O, Ellis LM.

Clin Adv Hematol Oncol. 2004 Jan;2(1):37-45. Review.

PMID:
16163158

Supplemental Content

Support Center